Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PURINETHOL vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Acute lymphoblastic leukemia (ALL) maintenance therapy (FDA-approved),Chronic myeloid leukemia (CML) (off-label),Inflammatory bowel disease (Crohn's disease, ulcerative colitis) (off-label),Autoimmune hepatitis (off-label)
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Primarily metabolized by xanthine oxidase (XO) to 6-thiouric acid (inactive), and via thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine (inactive). Activity of TPMT and NUDT15 affects toxicity. Allopurinol inhibits XO, leading to increased mercaptopurine levels.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 19% bound to plasma proteins, primarily albumin.
82–88% bound to plasma proteins (primarily albumin).
Volume of distribution is 0.9 L/kg, indicating distribution into total body water.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral bioavailability is highly variable, ranging from 5% to 37% (mean approximately 16%), due to extensive first-pass metabolism.
Oral: 65–80% (median 73%)
GFR 50-80 m L/min: reduce dose by 25-50%. GFR 10-50 m L/min: reduce dose by 50-75%. GFR <10 m L/min: administer 50% of normal dose every 48 hours or consider alternative.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Induction: 50-75 mg/m² orally once daily. Maintenance: 50-75 mg/m² orally once daily. Adjust based on tolerance and disease response.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Start at lower end of dosing range (1.5 mg/kg/day). Monitor renal function and hematologic parameters closely. Reduce dose if significant renal impairment present.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Severe myelosuppression, especially with TPMT or NUDT15 deficiency. The drug is myelotoxic; fatal myelosuppression can occur. Monitor blood counts frequently.
None
Myelosuppression: monitor CBCs regularly; reduce dose if severe.,TPMT/NUDT15 deficiency: increased risk of severe myelosuppression; consider testing before therapy.,Hepatotoxicity: monitor liver function tests; can cause hepatic veno-occlusive disease.,Immunosuppression: increased risk of infections.,Carcinogenicity: risk of secondary malignancies, especially with prolonged use.,Pregnancy: Category D; may cause fetal harm.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to mercaptopurine,Prior resistance to mercaptopurine (ineffective),Severe myelosuppression (unless benefits outweigh risks),Concomitant use with allopurinol (unless dose-adjusted due to toxicity risk),Pregnancy (absolute contraindication in some contexts)
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid grapefruit and grapefruit juice as they may increase drug levels. May decrease the effectiveness of warfarin; monitor INR if consuming vitamin K-rich foods. Alcohol consumption should be minimized due to potential hepatotoxicity.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intrauterine growth restriction, preterm delivery, and fetal myelosuppression. Overall, considered teratogenic in humans; avoid use unless benefit outweighs risk.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Present in breast milk in low concentrations. M/P ratio not established. Potential for infant myelosuppression and immunosuppression. Contraindicated in breastfeeding or use with caution; monitor infant for neutropenia and thrombocytopenia.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
Increased clearance during pregnancy may require dose adjustment. Monitor therapeutic drug levels (if available) and clinical response. Dose may need to be increased by up to 50% in second and third trimesters; post-partum reduce dose to pre-pregnancy levels.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Purinethol (6-mercaptopurine) is a prodrug converted to active thioguanine nucleotides. Co-administration with allopurinol requires a 65-75% dose reduction of Purinethol due to inhibition of xanthine oxidase. TPMT genotyping or phenotyping is recommended prior to initiation to avoid severe myelosuppression. Monitor CBC and liver enzymes regularly. Avoid live vaccines during therapy.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take this medication exactly as prescribed, usually once daily.,Do not take with allopurinol unless specifically instructed by your doctor, as it may increase side effects.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or jaundice immediately.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Drink plenty of fluids to prevent kidney stones from uric acid accumulation.,If you miss a dose, do not double the next dose; take it as soon as remembered if within 12 hours of scheduled time.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PURINETHOL vs AGRYLIN, answered by our medical review team.
PURINETHOL is a Antineoplastic Agent that works by Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PURINETHOL and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PURINETHOL is: 1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PURINETHOL and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PURINETHOL is classified as Category C. First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intraut. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.